Imagin Medical Inc.

Equities

IME

CA45250L2049

Biotechnology & Medical Research

Delayed Canadian Securities Exchange Other stock markets 19:29:20 02/02/2024 GMT			5-day change	1st Jan Change
0.015 ^CAD	-.--%		-.--%	-70.00%

2023	Imagin Medical Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	CI
2023	Imagin Medical Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	CI

Imagin Medical Names Ralph Devere to the Position of Chairman of the Scientific Medical Advisory Board

April 26, 2016 at 07:06 pm

Imagin Medical announced that Ralph DeVere White, M.D., has accepted the position of Chairman of the Company's Scientific Medical Advisory Board. Dr. deVere White is Associate Dean for Cancer Programs at UC Davis School of Medicine and Director of the UC Davis Comprehensive Cancer Center where he is also a professor of urology. Dr. deVere White is a Past President of the Society of Urologic Oncology.

Latest news about Imagin Medical Inc.

Imagin Medical Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	28/08/23	CI
Imagin Medical Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	24/05/23	CI
Imagin Medical Inc. Reports Earnings Results for the First Quarter Ended December 31, 2022	10/02/23	CI
Imagin Medical Inc. Reports Earnings Results for the Full Year Ended September 30, 2022	22/12/22	CI
Imagin Medical Inc. Auditor Raises 'Going Concern' Doubt	21/12/22	CI
Imagin Medical Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2022	29/08/22	CI
Imagin Medical Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2022	27/05/22	CI
Imagin Medical Inc. Reports Earnings Results for the First Quarter Ended December 31, 2021	18/02/22	CI
Imagin Medical Inc. Reports Earnings Results for the Full Year Ended September 30, 2021	24/12/21	CI
Imagin Medical Inc. Auditor Raises 'Going Concern' Doubt	23/12/21	CI
Imagin Medical Inc. Announces Board Changes	08/11/21	CI
Imagin Medical Inc. announced that it has received $2.9005 million in funding	25/08/21	CI
Imagin Medical Inc. Reports Earnings Results for the Third Quarter Ended June 30, 2021	20/08/21	CI
Imagin Medical Inc. Reports the Final Design of the i/Blue Imaging System Is on Target to Be Demonstrated At the American Urology Association Annual Meeting in September	17/08/21	CI
Imagin Medical Inc. Reports Earnings Results for the Second Quarter Ended March 31, 2021	26/05/21	CI
Imagin Medical Reports Company on Schedule for Product Demonstration	19/05/21	CI
Imagin Medical Inc. Reports Continued Progress Towards Commercial-Stage Manufacturing Capability with Lighthouse Imaging	16/03/21	CI
Imagin Medical Inc. Reports Earnings Results for the First Quarter Ended December 31, 2020	26/02/21	CI
Imagin Medical Inc. Reports Earnings Results for the Full Year Ended September 30, 2020	22/12/20	CI
Imagin Medical Inc. Auditor Raises 'Going Concern' Doubt	21/12/20	CI
Transcript : Imagin Medical Inc. - Special Call	29/10/20
Imagin Medical Inc. announced that it expects to receive $3 million in funding	21/10/20	CI
Imagin Medical Inc. Reports Earnings Results for the Third Quarter Ended June 30, 2020	28/08/20	CI
Imagin Medical to Begin Testing of i/BLUE TM Imaging System on Anatomical Bladder Models	15/07/20	CI
Transcript : Imagin Medical Inc., Q2 2020 Earnings Call, May 28, 2020	28/05/20

Chart Imagin Medical Inc.

Duration

Period

More charts

Company Profile

Imagin Medical Inc. is a urologic oncology company. It is engaged in developing technologies to better visualize and treat urologic cancers through minimally invasive surgery, including bladder and prostate cancer. Its first product, enCAGE Coil, is designed to eliminate the limitations of other methods of prostate cancer treatment that can cause erectile dysfunction and urinary incontinence. The device is a disposable, focal therapy, precision ablation system that will deliver bipolar, radio frequency energy through a distinctive coil electrode, or cage. It enables the surgeon to preset margins for precise tissue targeting. Its second product, the i/Blue Imaging System, will bring several key technological advancements that improve the utility of blue light imaging for visualizing bladder cancer. The i/Blue System delivers blue light imaging technology in a more versatile, practical, and accessible format and is designed to work with existing fiberoptic endoscopes on the market.

Sector

Biotechnology & Medical Research

Calendar

26/08/2024 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Medical Devices

	1st Jan change	Capi.
IMAGIN MEDICAL INC.	-70.00%	119K
NIBEC CO., LTD.	-24.30%	123M
COLLPLANT BIOTECHNOLOGIES LTD.	-20.19%	60.68M
KIM FOREST ENTERPRISE CO., LTD.	+0.41%	57.56M
NOVACYT	+14.45%	56.82M

Bio Medical Devices